Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTBCy for GVHD prophylaxis in refractory myeloid malignancies
NCT04943757Phase 2Completed
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Jan 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bendamustine, cyclophosphamide in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), Myeloproliferative Neoplasm (MPN), sponsored by First Saint Petersburg State Medical University. Started Jan 2021; status: completed.
02
Drugs
bendamustinecyclophosphamide
03
Conditions
acute myeloid leukemia (AML)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04943757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943757.